MedinCell S.A./€MEDCL
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About MedinCell S.A.
MedinCell S.A. is a pharmaceutical company focused on the development of long-acting injectable therapeutics. Operating in the healthcare industry, MedinCell specializes in drug delivery technology that combines global health needs with the potential for improved patient adherence. The company is known for its proprietary BEPO technology, which allows for controlled and sustained release of medication. Founded in 2002 and headquartered in Jacou, France, the company works on a pipeline of therapeutic solutions across various segments, including pain management, contraception, and mental health. MedinCell's strategic position is reinforced by its collaborative partnerships and its innovative approach to addressing unmet medical needs with affordable healthcare solutions.
Ticker
€MEDCL
Sector
Primary listing
PAR
Industry
Pharmaceuticals
Headquarters
Employees
131
ISIN
FR0004065605
Website
MedinCell S.A. Metrics
BasicAdvanced
€537M
-
-
1.07
-
Price and volume
Market cap
€537M
Beta
1.07
52-week high
€19.00
52-week low
€12.00
Average daily volume
89K
Financial strength
Interest coverage (TTM)
-2.12%
Profitability
EBITDA (TTM)
-9.868
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-66.50%
Operating margin (TTM)
-38.81%
Effective tax rate (TTM)
-0.88%
Revenue per employee (TTM)
€210,000
Management effectiveness
Valuation
Growth
Revenue change (TTM)
132.12%
3-year revenue growth (CAGR)
49.26%
Bulls say / Bears say
Analysts have significantly increased their revenue forecasts for MedinCell, projecting a 68% growth to €22 million in 2025, indicating strong confidence in the company's future performance. (webull.com)
MedinCell's partner, Teva Pharmaceuticals, reported positive Phase 3 efficacy results for TEV-‘749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia, potentially enhancing MedinCell's market position. (simplywall.st)
The market launch of UZEDY™ for the treatment of schizophrenia marks MedinCell's transition to a commercial-stage company, which could lead to increased revenues and market presence. (simplywall.st)
MedinCell reported a net loss of €8.44 million in March 2024, reflecting ongoing financial challenges that may impact investor confidence. (google.com)
The company's return on equity (ROE) decreased by 18.96% to 0.61 in 2025, indicating potential inefficiencies in generating profits from shareholders' equity. (eulerpool.com)
MedinCell's stock has experienced high volatility, with a 52-week range between €12.00 and €19.00, which may concern risk-averse investors. (cnbc.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MedinCell S.A. stock?
MedinCell S.A. (MEDCL) has a market cap of €537M as of July 11, 2025.
What is the P/E ratio for MedinCell S.A. stock?
The price to earnings (P/E) ratio for MedinCell S.A. (MEDCL) stock is 0 as of July 11, 2025.
Does MedinCell S.A. stock pay dividends?
No, MedinCell S.A. (MEDCL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next MedinCell S.A. dividend payment date?
MedinCell S.A. (MEDCL) stock does not pay dividends to its shareholders.
What is the beta indicator for MedinCell S.A.?
MedinCell S.A. (MEDCL) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.